-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Stride, Inc. (LRN)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN). The investigation concerns whether Stride and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On October 16, 2024, Fuzzy Panda Research published a report on Stride alleging that the Company inflated its earnings by misleading the market about the impact of federal COVID-19 relief funds. According to the report, 25% of the Company’s EBITDA came from Elementary and Secondary School Emergency Relief (ESSER) funds expiring in September 2024. The report also accuses Stride of hiding “ghost students” and failing to disclose schools leaving the Company, alongside allegations of overbilling and fraudulent reimbursement claims. On this news, the price of Stride shares declined by $6.55 per share, or approximately 9.3%, from $70.59 per share on October 15, 2024, to close at $64.04 on October 16, 2024.

If you purchased or otherwise acquired Stride securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:LRN

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Securities Class Action Filed Against Soleno Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) securities during the period of March 26, 2025 through November 4, 2025, inclusive (“the Class Period”). If you suffered a loss on your Soleno investments, you have until May 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submit...

REMINDER: NuScale Power Corporation Investors With Significant Losses Must Act By April 20, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds NuScale Power Corporation (“NuScale” or the “Company”) (NYSE:SMR) investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as...

INVESTOR ALERT: Securities Class Action Filed Against Eos Energy Enterprises, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Eos Energy Enterprises, Inc. (“Eos” or the “Company”) (NASDAQ:EOSE) period of November 5, 2025 through February 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Eos investments, you have until May 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadlin...
Back to Newsroom